Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Emerg Infect Dis. 2012 Nov;18(11):e2. doi: 10.3201/eid1811.120526.
In March 2012, in response to reports of tuberculosis (TB) resistant to all anti-TB drugs, the World Health Organization convened an expert consultation that identified issues to be resolved before defining a new category of highly drug-resistant TB. Proposed definitions are ambiguous, and extensive drug resistance is encompassed by the already defined extensively drug-resistant (XDR) TB. There is no evidence that proposed totally resistant TB differs from strains encompassed by XDR TB. Susceptibility tests for several drugs are poorly reproducible. Few laboratories can test all drugs, and there is no consensus list of all anti-TB drugs. Many drugs are used off-label for highly drug resistant TB, and new drugs formulated to combat resistant strains would render the proposed category obsolete. Labeling TB strains as totally drug resistant might lead providers to think infected patients are untreatable. These challenges must be addressed before defining a new category for highly drug-resistant TB.
2012 年 3 月,针对所有抗结核药物耐药的结核病报告,世界卫生组织召开了一次专家磋商,确定在定义新的耐多药结核病类别之前需要解决的问题。拟议的定义不明确,广泛耐药性已经涵盖了已经定义的广泛耐药性(XDR)结核病。没有证据表明拟议的完全耐药性与 XDR 结核病所涵盖的菌株不同。几种药物的药敏试验重现性差。很少有实验室可以检测所有药物,也没有所有抗结核药物的共识清单。许多药物被用于治疗耐多药结核病,而针对耐药菌株开发的新药可能会使拟议的类别过时。将结核菌株标记为完全耐药可能会导致提供者认为感染患者无法治疗。在定义耐多药结核病的新类别之前,必须解决这些挑战。